What To Expect From Y-mAbs Therapeutics Inc Q3 2024 Earnings

YMAB Stock  USD 11.88  1.11  10.31%   
About 54% of Y MAbs' investor base is interested to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are impartial. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Y-mAbs Therapeutics Inc is set to release its Q3 2024 earnings on Nov 8, 2024. The consensus estimate for Q3 2024 revenue is 23.26 million, and the earn

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Y MAbs Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Y MAbs Fundamental Analysis

We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Operating Margin

Operating Margin Comparative Analysis

Y MAbs is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Y mAbs Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.

Peers

Y MAbs Related Equities

KRONKronos Bio   10.34   
0%
96.0%
CCCCC4 Therapeutics   8.59   
0%
80.0%
LRMRLarimar Therapeutics   7.44   
0%
69.0%
ERASErasca   5.04   
0%
47.0%
ZNTLZentalis Pharmaceuticals   4.31   
0%
40.0%
BDTXBlack Diamond   4.05   
0%
37.0%
STROSutro Biopharma   3.46   
0%
32.0%
MIRMMirum Pharmaceuticals   3.32   
0%
31.0%
PCVXVaxcyte   2.77   
0%
25.0%
BLUEBluebird Bio   2.70   
0%
25.0%
ARQTArcutis Biotherapeutics   1.74   
0%
16.0%
DAWNDay One   1.33   
0%
12.0%
MRSNMersana Therapeutics   0.92   
0%
8.0%
EWTXEdgewise Therapeutics   0.37   
0%
3.0%
SNDXSyndax Pharmaceuticals   0.06   
0%
1.0%
RVMDRevolution Medicines   0.09   
1.0%
0%
GBIOGeneration Bio   0.69   
6.0%
0%
TVTXTravere Therapeutics   1.89   
17.0%
0%
MRUSMerus BV   1.96   
18.0%
0%
PASGPassage Bio   10.67   
100.0%
0%

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like